{"id":5108,"date":"2026-04-14T15:09:21","date_gmt":"2026-04-14T15:09:21","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/5108\/"},"modified":"2026-04-14T15:09:21","modified_gmt":"2026-04-14T15:09:21","slug":"amazon-launches-ai-research-tool-to-speed-early-stage-drug-discovery","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/5108\/","title":{"rendered":"Amazon Launches AI Research Tool to Speed Early-Stage Drug Discovery"},"content":{"rendered":"

By Sahil Pandey and Puyaan Singh<\/p>\n

April 14 (Reuters) – Amazon’s cloud \u2060unit \u2060on Tuesday launched Amazon \u2060Bio Discovery, an artificial intelligence application designed to speed early-stage \u200bdrug discovery by allowing scientists to run complex computational workflows without writing code.<\/p>\n

Drugmakers and technology \u200ccompanies have stepped up efforts to \u200cuse AI to accelerate drug development.<\/p>\n

Amazon Web Services said in a blog post \u2060that Amazon \u2060Bio Discovery gives researchers access to a library of specialized biological \u200bfoundation models that can generate and evaluate potential drug molecules, along with an AI agent that helps users select models, set parameters and interpret results.<\/p>\n

Researchers can send shortlisted candidates to \u200bintegrated lab partners for synthesis and testing, with results routed back into the \u2060system \u2060to guide the next round \u2060of design.<\/p>\n

“(It) \u200bwould take, 18 months to come up with 300 potential drug candidates. Now, scientists \u200bcan quickly create 300 \u2060candidates within a couple of weeks,” Rajiv Chopra, vice president of healthcare AI and life sciences at AWS, said in an interview with Reuters.<\/p>\n

Chopra said the rapid rise of drug-discovery models has turned computational biologists who can translate lab goals into machine-learning \u2060pipelines into a bottleneck.<\/p>\n

AWS said Bayer, the Broad Institute and Voyager Therapeutics \u2060are among early adopters, and 19 of the top 20 global pharmaceutical companies already use its cloud services.<\/p>\n

In a collaboration with Memorial Sloan Kettering Cancer Center, AWS said the platform used multiple models to generate nearly 300,000 novel antibody molecules and narrow them to 100,000 candidates for lab testing by partner Twist Bioscience , compressing work that can take months into weeks.<\/p>\n

Chopra said the service is intended to augment, not replace, scientists and contract research \u2060organizations.<\/p>\n

AWS will offer a free trial with five experimental units before introducing subscription tiers.<\/p>\n

AWS, Boston Consulting Group and Merck will also unveil an AI platform at AWS’s Life Science Symposium aimed at improving clinical trial site selection, \u200ba common bottleneck in drug development.<\/p>\n

(Reporting by Sahil Pandey and Puyaan \u200bSingh in Bengaluru; Editing by Tasim Zahid)<\/p>\n

Copyright 2026 Thomson Reuters.<\/p>\n

Photos You Should See \u2013 April 2026<\/p>\n

\"A<\/p>\n","protected":false},"excerpt":{"rendered":"By Sahil Pandey and Puyaan Singh April 14 (Reuters) – Amazon’s cloud \u2060unit \u2060on Tuesday launched Amazon \u2060Bio…\n","protected":false},"author":2,"featured_media":5109,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,25,3589,4661,700,2267,4574,214],"class_list":["post-5108","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ai","tag-ai","tag-artificial-intelligence","tag-collections-top-news","tag-denmark","tag-europe","tag-reuters","tag-top-news","tag-united-states"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/5108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=5108"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/5108\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/5109"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=5108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=5108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=5108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}